QuidelOrtho Reports Q2 2026 Revenue Increase and Net Loss Improvement

QuidelOrtho Corporation reported its financial results for the second quarter of 2026, revealing total revenues of $630.9 million, a 3% increase from $613.9 million in the same period last year. For the first half of 2026, revenues decreased by 4% to $1,250.7 million compared to $1,306.7 million in the prior year. The decline was attributed to reduced sales of respiratory products, particularly due to lower demand for flu and COVID-19 testing, the termination of a joint business arrangement, and evolving market conditions in China. The company also noted that revenues from respiratory products accounted for 9% of total revenues in the first half of 2026, down from 13% in the same period of 2025.

The company experienced a net loss of $92.9 million for the second quarter, compared to a loss of $255.4 million in the same quarter of the previous year. For the first half of 2026, the net loss was $184.7 million, an improvement from a loss of $268.1 million in the first half of 2025. The reduction in losses was attributed to lower restructuring and integration charges, which fell significantly from $178.9 million in the second quarter of 2025 to $6.5 million in the same quarter of 2026. Operating expenses also increased, with selling, marketing, and administrative expenses rising to $189.7 million, reflecting higher distribution and employee compensation costs.

In terms of strategic developments, QuidelOrtho completed the acquisition of LEX Diagnostics in April 2026 for $174.6 million, which included the LEX VELO System technology aimed at enhancing its molecular diagnostics portfolio. The company is also in the process of winding down its U.S. donor screening portfolio, which has contributed to a significant drop in related revenues. The restructuring efforts are part of a broader Optimization Plan aimed at achieving approximately $50 million in cost savings by 2027.

Operationally, QuidelOrtho's total assets decreased to $5.72 billion as of June 28, 2026, down from $5.77 billion at the end of 2025. The company reported a decrease in cash and cash equivalents to $123.4 million, down from $169.8 million. The total liabilities increased to $3.94 billion, primarily due to an increase in current borrowings. The company’s employee headcount remained stable, with a focus on optimizing its workforce in line with its strategic initiatives.

Looking ahead, QuidelOrtho anticipates continued fluctuations in demand for its respiratory and non-respiratory products, influenced by seasonal trends and market dynamics. The company plans to leverage its recent acquisition and ongoing restructuring efforts to enhance its product offerings and operational efficiencies. However, it remains cautious about potential impacts from macroeconomic factors, including tariffs and regulatory changes, particularly in the Chinese market. The company expects to maintain sufficient liquidity to support its operational and capital needs over the next 12 months, with a focus on strategic growth and cost management.